Cart
0
Get 20% Free Customization In This Report
Buy this report from - $3255

U.S. Next Generation Diabetes Therapy and Drug Delivery Market by Product Type (Inhalable Insulin, Oral Insulin, Insulin Patch, CGM System, and Artificial Pancreas), Demographic (Adult Population and Child Population), Indication (Type I Diabetes and Type II Diabetes), and End User (Diagnostics/Clinic, ICU, and Home Healthcare) - U.S. Opportunity Analysis and Industry Forecast, 2014-2023

LI 184621
Pages: 124
Apr 2018 | 975 Views
face gplus_n
Author's : Tenzin Kunsel and Onkar Sumant
Tables: 31
Charts: 37
twit_n pr_n

Next generation diabetic therapy and drug delivery market Overview:

Next generation diabetic therapy and drug delivery systems are used to improve the adherence to insulin in a diabetic patient, which in turn helps reduce the risk of complications related to sudden changes in blood sugar level. As oral and inhalable insulin helps to painlessly manage the blood glucose level, they have the potential to replace injectable insulins. Advanced diabetic therapy in the form of insulin patches, continuous glucose monitoring systems (CGMS), and artificial pancreas help improve management of blood sugar level and reduces the risk of any diabetic-related complications. The U.S. next generation diabetes therapy and drug delivery market was valued at $446 million in 2015, and is estimated to reach $6,510 million by 2023, registering a CAGR of 33.0% from 2017 to 2023.

The U.S. next generation diabetes therapy and drug delivery market growth is attributed to the rise in the number of diabetic patients in the U.S. along with the increase in disposable income among the diabetic patients. The benefits of using these advanced devices over conventional products and rise in the healthcare expenditure are expected to increase the demand for these advanced diabetic products, thus fueling the market growth. However, cost restraints among low and middle-income population and less variability in products are expected to hamper this growth.

Product segment review

Based on the products, the market is segmented into inhalable insulin, oral insulin, insulin patches, CGM systems, and artificial pancreas. CGM systems segment dominates the market owing to the availability of large number of FDA approved CGM devices leading to high adoption rate of these devices.

by product

Get more information on this report : Request Sample Pages

Demographics segment review

Depending on demographics, the market is bifurcated into adult and child population. Adult population is the dominant segment that contributes toward the market growth as almost 90% of the diabetic population in U.S. are above the age of 18 years.

by demographics

Get more information on this report : Request Sample Pages

The key players profiled in this report include Abbott Laboratories, Echo Therapeutics, Inc., F. Hoffmann-La Roche Ltd., GlySens Incorporated, Medtronic Plc, Sanofi, Novo Nordisk, MannKind Corporation, Dexcom, Inc., and Senseonics Holding, Inc.

Other players in the value chain include Enteris BioPharma, Synertech, Zosano Pharma Corp., Relmada Therapeutics, Inc., Eli Lilly and Company, and Transdermal Specialties Inc.

Key Benefits

  • This report entails a detailed quantitative analysis of the current market trends from 2014 to 2023 to identify the prevailing opportunities.
  • Market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
  • The U.S. next generation diabetes therapy and drug delivery market is comprehensively analyzed with respect to product type, demographics, indication, and end user.
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

U.s. Next Generation Diabetes Therapy And Drug Delivery Market Key Segments:

By Product Type

  • Inhalable Insulin
  • Oral Insulin
  • Insulin Patch
  • CGM System
  • Artificial Pancreas

By Demographic

  • Adult Population (>14years)
  • Child Population (14years)

By Indication

  • Type I Diabetes
  • Type II Diabetes

By End User

  • Diagnostics/Clinic
  • ICU
  • Home Healthcare
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. KEY BENEFITS

3.1.1. Top investment pockets
3.1.2. Top winning strategies

3.2. PATENT ANALYSIS

3.2.1. Patent analysis by year
3.2.2. Patent analysis by product

3.3. GOVERNMENT REGULATIONS

3.3.1. U.S. FDA

3.4. REIMBURSEMENT POLICIES
3.5. INNOVATIONS IN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET

3.5.1. Smart contact lenses for glucose monitoring
3.5.2. iLet bihormonal bionic pancreas
3.5.3. Glucose nanosensors
3.5.4. Beta cell replacement therapy
3.5.5. Glucose-responsive insulin-producing cells

3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Rise in incidence of diabetes
3.6.1.2. Rise in healthcare expenditure & disposable income
3.6.1.3. Benefits of using next generation diabetes products over conventional products

3.6.2. Restraints

3.6.2.1. Cost restrains
3.6.2.2. Lack of awareness
3.6.2.3. Less variability in products

3.6.3. Opportunities

3.6.3.1. Developing products with fewer side effects at affordable costs
3.6.3.2. High undiagnosed diabetic patient population

Chapter: 4 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. INHALABLE INSULIN

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. ORAL INSULIN

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. INSULIN PATCHES

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

4.5. CGMS

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast

4.6. ARTIFICIAL PANCREAS

4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast

Chapter: 5 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ADULT POPULATION (>14YEARS)

5.2.1. Market size and forecast

5.3. CHILD POPULATION (≤14YEARS)

5.3.1. Market size and forecast

Chapter: 6 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. TYPE I DIABETES

6.2.1. Market size and forecast

6.3. TYPE II DIABETES

6.3.1. Market size and forecast

Chapter: 7 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. DIAGNOSTICS/CLINICS

7.2.1. Market size and forecast

7.3. INTENSIVE CARE UNITS (ICU)

7.3.1. Market size and forecast

7.4. HOME HEALTHCARE

7.4.1. Market size and forecast

Chapter: 8 COMPANY PROFILES

8.1. ABBOTT LABORATORIES

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments

8.2. DEXCOM, INC.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Product portfolio
8.2.4. Business performance
8.2.5. Key strategic moves and developments

8.3. ECHO THERAPEUTICS, INC.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio

8.4. F. HOFFMANN-LA ROCHE LTD.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments

8.5. GLYSENS INCORPORATED

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Product portfolio
8.5.4. Key strategic moves and developments

8.6. MANNKIND CORPORATION

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance

8.7. MEDTRONIC PLC.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. NOVO NORDISK A/S

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance

8.9. SANOFI

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments

8.10. SENSEONICS HOLDINGS, INC.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments

LIST OF TABLES

TABLE 1. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,  BY PRODUCT, 2014-2023 ($THOUSAND)
TABLE 2. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,  BY DEMOGRAPHICS, 2014-2023 ($THOUSAND)
TABLE 3. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,  BY INDICATION, 2014-2023 ($THOUSAND)
TABLE 4. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2014-2023 ($THOUSAND)
TABLE 5. ABBOTT: COMPANY SNAPSHOT
TABLE 6. ABBOTT: OPERATING SEGMENTS
TABLE 7. ABBOTT: PRODUCT PORTFOLIO
TABLE 8. DEXCOM: COMPANY SNAPSHOT
TABLE 9. DEXCOM: PRODUCT PORTFOLIO
TABLE 10. ECHO THERAPEUTICS: COMPANY SNAPSHOT
TABLE 11. ECHO THERAPEUTICS: OPERATING SEGMENTS
TABLE 12. ECHO THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 13. ROCHE: COMPANY SNAPSHOT
TABLE 14. ROCHE: OPERATING SEGMENTS
TABLE 15. ROCHE: PRODUCT PORTFOLIO
TABLE 16. GLYSENS: COMPANY SNAPSHOT
TABLE 17. GLYSENS: PRODUCT PORTFOLIO
TABLE 18. MANNKIND: COMPANY SNAPSHOT
TABLE 19. MANNKIND: PRODUCT PORTFOLIO
TABLE 20. MEDTRONIC: COMPANY SNAPSHOT
TABLE 21. MEDTRONIC: OPERATING SEGMENTS
TABLE 22. MEDTRONIC: PRODUCT PORTFOLIO
TABLE 23. NOVO NORDISK: COMPANY SNAPSHOT
TABLE 24. NOVO NORDISK: OPERATING SEGMENTS
TABLE 25. NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 26. SANOFI: COMPANY SNAPSHOT
TABLE 27. SANOFI: OPERATING SEGMENTS
TABLE 28. SANOFI: PRODUCT PORTFOLIO
TABLE 29. SENSEONICS: COMPANY SNAPSHOT
TABLE 30. SENSEONICS: PRODUCT SEGMENTS
TABLE 31. SENSEONICS: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET: SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS, BY PRODUCT
FIGURE 3. TOP WINNING STRATEGIES, BY YEAR, 2015-2018*
FIGURE 4. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2018* (%)
FIGURE 5. TOP WINNING STRATEGIES, BY COMPANY, 2015-2018*
FIGURE 6. PATENT REGISTERED/APPROVED, BY YEAR
FIGURE 7. PATENT REGISTERED/APPROVED, BY PRODUCT
FIGURE 8. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR INHALABLE INSULIN, 2014-2023 ($THOUSAND)
FIGURE 9. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR ORAL INSULIN, 2014-2023 ($THOUSAND)
FIGURE 10. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR INSULIN PATCH, 2014-2023 ($THOUSAND)
FIGURE 11. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR CGM SYSTEMS, 2014-2023 ($THOUSAND)
FIGURE 12. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR ARTIFICIAL PANCREAS, 2014-2023 ($THOUSAND)
FIGURE 13. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR ADULT POPULATION, 2014-2023 ($THOUSAND)
FIGURE 14. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR CHILD POPULATION, 2014-2023 ($THOUSAND)
FIGURE 15. NEXT GENERATION TYPE I DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 ($THOUSAND)
FIGURE 16. NEXT GENERATION TYPE II DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 ($THOUSAND)
FIGURE 17. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR DIAGNOSTICS/CLINICS, 2014-2023 ($THOUSAND)
FIGURE 18. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR ICUS, 2014-2023 ($THOUSAND)
FIGURE 19. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR HOME HEALTHCARE, 2014-2023 ($THOUSAND)
FIGURE 20. ABBOTT: NET SALES, 2015-2017 ($MILLION)
FIGURE 21. ABBOTT: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 22. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 23. DEXCOM: NET SALES, 2015-2017 ($MILLION)
FIGURE 24. DEXCOM: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 25. ROCHE: NET SALES, 2015-2017 ($MILLION)
FIGURE 26. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 27. MANNKIND: NET SALES, 2016-2017 ($MILLION)
FIGURE 28. MEDTRONIC: NET SALES, 2015-2017 ($MILLION)
FIGURE 29. MEDTRONIC: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 30. MEDTRONIC: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 31. NOVO NORDISK: NET SALES, 2015-2017 ($MILLION)
FIGURE 32. NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 33. NOVO NORDISK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 34. SANOFI: NET SALES, 2015-2017 ($MILLION)
FIGURE 35. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 36. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 37. SENSEONICS: NET SALES, 2015-2017 ($MILLION)

 

Oral and inhalable insulin reduces the risk of skin irritation due to needles as well as is a painless mode of insulin delivery. This in turn increases the demand in the market. Therefore, they are also expected to replace injectable insulins.

With the advancement in diabetic therapy systems such as insulin patches and artificial pancreas, the amount of insulin that needs to be introduced into the patients’ body is adjusted according to the blood sugar levels using a computer algorithm. The automated version of these systems help the patient lead a normal life and reduce the complications related to hypo- or hyperglycemia. Such advancement in diabetic technology is expected to help boosts the growth of the market.

The use of other advanced diabetic systems such as insulin patch, CGM system, and artificial pancreas help in adherence to medication in diabetic patients and improve the quality of life of diabetic patients. The U.S. next generation diabetes therapy and drug delivery market is expected to experience an exponential growth owing to increase in demand for advanced diabetic products, high incidence of diabetes in U.S., and rise in healthcare expenditure.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Request sample

OR

Purchase Full Report of
U.S. Next Generation Diabetes Therapy and Drug Delivery Market

  • Data Pack
  • $2355
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $3255
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $3910
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $5452
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo